Patents Assigned to Genzyme Coporation
  • scFv-Fc dimers that bind transforming growth factor-?1 with high affinity, avidity and specificity
    Patent number: 11976112
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Grant
    Filed: April 4, 2022
    Date of Patent: May 7, 2024
    Assignee: Genzyme Coporation
    Inventors: Huawei Qiu, Clark Pan, Julie Bird